Caroline Dive

List of Publications by Year
in descending order

94 papers	13,960 citations	61857 43 h-index	38300 95 g-index
97 all docs	97 docs citations	97 times ranked	20139 citing authors

#	Article	IF	Citations
1	Expanding Therapeutic Opportunities for Extrapulmonary Neuroendocrine Carcinoma. Clinical Cancer Research, 2022, 28, 1999-2019.	3.2	20
2	Early detection of cancer. Science, 2022, 375, eaay9040.	6.0	291
3	A conserved YAP/Notch/REST network controls the neuroendocrine cell fate in the lungs. Nature Communications, 2022, 13, 2690.	5.8	19
4	Establishment of CORONET, COVID-19 Risk in Oncology Evaluation Tool, to Identify Patients With Cancer at Low Versus High Risk of Severe Complications of COVID-19 Disease On Presentation to Hospital. JCO Clinical Cancer Informatics, 2022, , .	1.0	7
5	Small cell lung cancer enters the era of precision medicine. Cancer Cell, 2021, 39, 297-299.	7.7	31
6	Early Dissemination of Circulating Tumor Cells: Biological and Clinical Insights. Frontiers in Oncology, 2021, 11, 672195.	1.3	34
7	Progress towards non-small-cell lung cancer models that represent clinical evolutionary trajectories. Open Biology, 2021, 11, 200247.	1.5	28
8	Soluble guanylate cyclase signalling mediates etoposide resistance in progressing small cell lung cancer. Nature Communications, 2021, 12, 6652.	5.8	14
9	TIAM1-RAC1 promote small-cell lung cancer cell survival through antagonizing Nur77-induced BCL2 conformational change. Cell Reports, 2021, 37, 109979.	2.9	13
10	Profiling of Circulating Free DNA Using Targeted and Genome-wide Sequencing in Patients with SCLC. Journal of Thoracic Oncology, 2020, 15, 216-230.	0.5	49
11	Brief report on the clinical characteristics of patients whose samples generate small cell lung cancer circulating tumour cell derived explants. Lung Cancer, 2020, 150, 216-220.	0.9	7
12	Impact of Lineage Plasticity to and from a Neuroendocrine Phenotype on Progression and Response in Prostate and Lung Cancers. Molecular Cell, 2020, 80, 562-577.	4.5	54
13	The Rare YAP1 Subtype of SCLC Revisited in a Biobank of 39 Circulating Tumor Cell Patient Derived Explant Models: A Brief Report. Journal of Thoracic Oncology, 2020, 15, 1836-1843.	0.5	45
14	Representative Sequencing: Unbiased Sampling of Solid Tumor Tissue. Cell Reports, 2020, 31, 107550.	2.9	51
15	New Approaches to SCLC Therapy: From the Laboratory to the Clinic. Journal of Thoracic Oncology, 2020, 15, 520-540.	0.5	119
16	Pazopanib and Fosbretabulin in recurrent ovarian cancer (PAZOFOS): A multi-centre, phase 1b and open-label, randomised phase 2 trial. Gynecologic Oncology, 2020, 156, 545-551.	0.6	14
17	Liquid Biopsy-Based Biomarkers of Treatment Response and Resistance. Cancer Cell, 2020, 37, 485-495.	7.7	223
18	A biobank of small cell lung cancer CDX models elucidates inter- and intratumoral phenotypic heterogeneity. Nature Cancer, 2020, 1, 437-451.	5.7	103

#	Article	IF	Citations
19	Ex vivo culture of cells derived from circulating tumour cell xenograft to support small cell lung cancer research and experimental therapeutics. British Journal of Pharmacology, 2019, 176, 436-450.	2.7	34
20	Analysis of circulating cell-free DNA identifies KRAS copy number gain and mutation as a novel prognostic marker in Pancreatic cancer. Scientific Reports, 2019, 9, 11610.	1.6	36
21	Identification of a Biomarker Panel for Early Detection of Lung Cancer Patients. Journal of Proteome Research, 2019, 18, 3369-3382.	1.8	22
22	Evaluation of apoptosis imaging biomarkers in a genetic model of cell death. EJNMMI Research, 2019, 9, 18.	1.1	9
23	Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse. Nature Medicine, 2019, 25, 1534-1539.	15.2	146
24	Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study. Nature Medicine, 2019, 25, 738-743.	15.2	202
25	Dynamics of circulating vascular endothelial growth factorâ€A predict benefit from antiangiogenic cediranib in metastatic or recurrent cervical cancer patients. British Journal of Clinical Pharmacology, 2019, 85, 1781-1789.	1.1	3
26	Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. Nature Reviews Cancer, 2019, 19, 289-297.	12.8	692
27	Molecular characterisation and liquid biomarkers in Carcinoma of Unknown Primary (CUP): taking the â€˜Uâ€™ out of â€˜CUPâ€™. British Journal of Cancer, 2019, 120, 141-153.	2.9	71
28	Genomic Evaluation of Multiparametric Magnetic Resonance Imaging-visible and -nonvisible Lesions in Clinically Localised Prostate Cancer. European Urology Oncology, 2019, 2, 1-11.	2.6	27
29	In silico error correction improves cfDNA mutation calling. Bioinformatics, 2019, 35, 2380-2385.	1.8	6
30	Cell Death, Inflammation, Tumor Burden, and Proliferation Blood Biomarkers Predict Lung Cancer Radiotherapy Response and Correlate With Tumor Volume and Proliferation Imaging. Clinical Lung Cancer, 2018, 19, 239-248.e7.	1.1	16
31	Plasma Tie2 is a tumor vascular response biomarker for VEGF inhibitors in metastatic colorectal cancer. Nature Communications, 2018, 9, 4672.	5.8	47
32	Will liquid biopsies improve outcomes for patients with small-cell lung cancer?. Lancet Oncology, The, 2018, 19, e470-e481.	5.1	63
33	The Combination of the PARP Inhibitor Olaparib and the WEE1 Inhibitor AZD1775 as a New Therapeutic Option for Small Cell Lung Cancer. Clinical Cancer Research, 2018, 24, 5153-5164.	3.2	126
34	Signaling pathway screening platforms are an efficient approach to identify therapeutic targets in cancers that lack known driver mutations: a case report for a cancer of unknown primary origin. Npj Genomic Medicine, 2018, 3, 15.	1.7	9
35	Circulating Biomarkers and Resistance to Endocrine Therapy in Metastatic Breast Cancers: Correlative Results from AZD9496 Oral SERD Phase I Trial. Clinical Cancer Research, 2018, 24, 5860-5872.	3.2	44
36	twoddpcr: an R/Bioconductor package and Shiny app for Droplet Digital PCR analysis. Bioinformatics, 2017, 33, 2743-2745.	1.8	26

#	Article	IF	Citations
37	Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature, 2017, 545, 446-451.	13.7	1,287
38	Tracking the Evolution of Nonâ€“Small-Cell Lung Cancer. New England Journal of Medicine, 2017, 376, 2109-2121.	13.9	1,786
39	Next-Generation Sequencing Analysis and Algorithms for PDX and CDX Models. Molecular Cancer Research, 2017, 15, 1012-1016.	1.5	49
40	OA05.07 Prognostic Value of Circulating Tumor Cells in Limited-Disease Small Cell LungÂCancer Patients Treated on the CONVERT Trial. Journal of Thoracic Oncology, 2017, 12, S263.	0.5	2
41	Progress and prospects of early detection in lung cancer. Open Biology, 2017, 7, 170070.	1.5	552
42	Molecular analysis of single circulating tumour cells following longâ€term storage of clinical samples. Molecular Oncology, 2017, 11, 1687-1697.	2.1	12
43	PDGFR-modulated miR-23b cluster and miR-125a-5p suppress lung tumorigenesis by targeting multiple components of KRAS and NF-kB pathways. Scientific Reports, 2017, 7, 15441.	1.6	49
44	Targeting DNA damage in SCLC. Lung Cancer, 2017, 114, 12-22.	0.9	36
45	Imaging biomarker roadmap for cancer studies. Nature Reviews Clinical Oncology, 2017, 14, 169-186.	12.5	792
46	Molecular analysis of circulating tumor cells identifies distinct copy-number profiles in patients with chemosensitive and chemorefractory small-cell lung cancer. Nature Medicine, 2017, 23, 114-119.	15.2	260
47	Circulating tumor cells and CDX models as a tool for preclinical drug development. Translational Lung Cancer Research, 2017, 6, 397-408.	1.3	68
48	The clinical utility of circulating tumour cells in patients with small cell lung cancer. Translational Lung Cancer Research, 2017, 6, 409-417.	1.3	28
49	Novel risk models for early detection and screening of ovarian cancer. Oncotarget, 2017, 8, 785-797.	0.8	13
50	Short duration immunochemotherapy followed by radioimmunotherapy consolidation is effective and well tolerated in relapsed follicular lymphoma: 5â€year results from a <scp>UK</scp> National Cancer Research Institute Lymphoma Group study. British Journal of Haematology, 2016, 173, 274-282.	1.2	12
51	Systematic analysis of circulating soluble angiogenesis-associated proteins in ICON7 identifies Tie2 as a biomarker of vascular progression on bevacizumab. British Journal of Cancer, 2016, 115, 228-235.	2.9	23
52	Hypoxia-driven splicing into noncoding isoforms regulates the DNA damage response. Npj Genomic Medicine, 2016, 1, 16020.	1.7	22
53	Inhibition of PI3K/BMX Cell Survival Pathway Sensitizes to BH3 Mimetics in SCLC. Molecular Cancer Therapeutics, 2016, 15, 1248-1260.	1.9	30
54	Identification and Targeting of Long-Term Tumor-Propagating Cells in Small Cell Lung Cancer. Cell Reports, 2016, 16, 644-656.	2.9	73

#	Article	IF	Citations
55	Protein Z: A putative novel biomarker for early detection of ovarian cancer. International Journal of Cancer, 2016, 138, 2984-2992.	2.3	41
56	Circulating Tumor Cells Detected in the Tumor-Draining Pulmonary Vein Are Associated with Disease Recurrence after Surgical Resection of NSCLC. Journal of Thoracic Oncology, 2016, 11, 1793-1797.	0.5	80
57	Vasculogenic mimicry in small cell lung cancer. Nature Communications, 2016, 7, 13322.	5.8	206
58	Somatically mutated <scp>ABL</scp>1 is an actionable and essential <scp>NSCLC</scp> survival gene. EMBO Molecular Medicine, 2016, 8, 105-116.	3.3	18
59	Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?. Journal of Thoracic Oncology, 2016, 11, 453-474.	0.5	156
60	Genetic profiling of tumours using both circulating free DNA and circulating tumour cells isolated from the same preserved whole blood sample. Molecular Oncology, 2016, 10, 566-574.	2.1	74
61	Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma. Cancer Discovery, 2016, 6, 286-299.	7.7	208
62	Development of a circulating miRNA assay to monitor tumor burden: From mouse to man. Molecular Oncology, 2016, 10, 282-291.	2.1	18
63	Clinical evaluation of a novel microfluidic device for epitope-independent enrichment of circulating tumour cells in patients with small cell lung cancer. Analyst, The, 2016, 141, 669-678.	1.7	95
64	Optimisation of immunofluorescence methods to determine MCT1 and MCT4 expression in circulating tumour cells. BMC Cancer, 2015, 15, 387.	1.1	9
65	Diagnostic Mutation Profiling and Validation of Nonâ€“Small-Cell Lung Cancer Small Biopsy Samples using a High Throughput Platform. Journal of Thoracic Oncology, 2015, 10, 784-792.	0.5	16
66	Discovery and Validation of Predictive Biomarkers of Survival for Non-small Cell Lung Cancer Patients Undergoing Radical Radiotherapy: Two Proteins With Predictive Value. EBioMedicine, 2015, 2, 841-850.	2.7	24
67	Circulating Tumor Cell Enumeration in a Phase II Trial of a Four-Drug Regimen in Advanced Colorectal Cancer. Clinical Colorectal Cancer, 2015, 14, 115-122.e2.	1.0	43
68	Quantification of skeletal metastases in castrateâ€resistant prostate cancer predicts progressionâ€free and overall survival. BJU International, 2014, 114, E70-E73.	1.3	30
69	The Combination of Circulating Ang1 and Tie2 Levels Predicts Progression-Free Survival Advantage in Bevacizumab-Treated Patients with Ovarian Cancer. Clinical Cancer Research, 2014, 20, 4549-4558.	3.2	63
70	An Integrated Characterization of Serological, Pathological, and Functional Events in Doxorubicin-Induced Cardiotoxicity. Toxicological Sciences, 2014, 140, 3-15.	1.4	47
71	Analytical Validation of BRAF Mutation Testing from Circulating Free DNA Using the Amplification Refractory Mutation Testing System. Journal of Molecular Diagnostics, 2014, 16, 343-349.	1.2	44
72	Molecular analysis of circulating tumour cellsâ€”biology and biomarkers. Nature Reviews Clinical Oncology, 2014, 11, 129-144.	12.5	535

#	Article	IF	Citations
73	Activity of the Monocarboxylate Transporter 1 Inhibitor AZD3965 in Small Cell Lung Cancer. Clinical Cancer Research, 2014, 20, 926-937.	3.2	256
74	Optimisation of an immunohistochemistry method for the determination of androgen receptor expression levels in circulating tumour cells. BMC Cancer, 2014, 14, 226.	1.1	13
75	Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer. Nature Medicine, 2014, 20, 897-903.	15.2	608
76	BMX Acts Downstream of PI3K to Promote Colorectal Cancer Cell Survival and Pathway Inhibition Sensitizes to the BH3 Mimetic ABT-737. Neoplasia, 2014, 16, 147-W16.	2.3	22
77	Biomarker Utility of Circulating Tumor Cells in Metastatic Cutaneous Melanoma. Journal of Investigative Dermatology, 2013, 133, 1582-1590.	0.3	122
78	Method validation of circulating tumour cell enumeration at low cell counts. BMC Cancer, 2013, 13, 415.	1.1	20
79	Prognostic and predictive biomarkers in early stage NSCLC: CTCs and serum/plasma markers. Translational Lung Cancer Research, 2013, 2, 382-97.	1.3	29
80	Analysis of Circulating Tumor Cells in Patients with Non-small Cell Lung Cancer Using Epithelial Marker-Dependent and -Independent Approaches. Journal of Thoracic Oncology, 2012, 7, 306-315.	0.5	411
81	Clinical Significance and Molecular Characteristics of Circulating Tumor Cells and Circulating Tumor Microemboli in Patients With Small-Cell Lung Cancer. Journal of Clinical Oncology, 2012, 30, 525-532.	0.8	755
82	Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer. Clinical Cancer Research, 2012, 18, 3163-3169.	3.2	470
83	Evaluation and Prognostic Significance of Circulating Tumor Cells in Patients With Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2011, 29, 1556-1563.	0.8	788
84	The Novel Bcl-2 Inhibitor ABT-737 Is More Effective in Hypoxia and Is Able to Reverse Hypoxia-Induced Drug Resistance in Neuroblastoma Cells. Molecular Cancer Therapeutics, 2011, 10, 2373-2383.	1.9	27
85	Hypoxic human cancer cells are sensitized to BH-3 mimeticâ€“induced apoptosis via downregulation of the Bcl-2 protein Mcl-1. Journal of Clinical Investigation, 2011, 121, 1075-1087.	3.9	46
86	Blocking Phosphoinositide 3-Kinase Activity in Colorectal Cancer Cells Reduces Proliferation but Does Not Increase Apoptosis Alone or in Combination with Cytotoxic Drugs. Molecular Cancer Research, 2009, 7, 955-965.	1.5	22
87	Evaluation of Circulating Tumor Cells and Serological Cell Death Biomarkers in Small Cell Lung Cancer Patients Undergoing Chemotherapy. American Journal of Pathology, 2009, 175, 808-816.	1.9	223
88	Comparison of phosphatidylinositol-3-kinase signalling within a panel of human colorectal cancer cell lines with mutant or wild-type PIK3CA. FEBS Letters, 2005, 579, 5123-5128.	1.3	28
89	Cellular damage signals promote sequential changes at the N-terminus and BH-1 domain of the pro-apoptotic protein Bak. Oncogene, 2001, 20, 7668-7676.	2.6	84
90	Bcr-Abl protein tyrosine kinase activity induces a loss of p53 protein that mediates a delay in myeloid differentiation. Oncogene, 2000, 19, 5487-5497.	2.6	31

#	Article	IF	Citations
91	Cell Damage-induced Conformational Changes of the Pro-Apoptotic Protein Bak In Vivo Precede the Onset of Apoptosis. Journal of Cell Biology, 1999, 144, 903-914.	2.3	413
92	Cell cycle specific induction of HL-60 cell differentiation and apoptosis by mycophenolic acid. Cell Death and Differentiation, 1997, 4, 787-795.	5.0	11
93	MCF-7 human mammary adenocarcinoma cell deathin vitro in response to hormone-withdrawal and dna damage. International Journal of Cancer, 1995, 61, 502-508.	2.3	51
94	Cellular damage signals promote sequential changes at the N-terminus and BH-1 domain of the pro-apoptotic protein Bak. , 0, .		1